Sanofi Pasteur and Statens Serum Institut Team Up Against Tu...( intentionsand expectations with respect...)

Date:2/14/2008

, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.
(1) http://www.who.int/mediacentre/factsheets/fs104/en/index.html

(2) http://www.globalhealthreporting.org/tb.asp

sanofi pasteur

Pascal Barollier

Relations Presse

Tel : +33-4-37-37-51-41

pascal.barollier@sanofipasteur.com

Media Relations:

Tel.: +33-4-37-37-50-38

'/>"/>

SOURCE Sanofi Pasteur Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
3. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
4. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Pasteuria Bioscience Taps New CEO David N. Duncan
6. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
7. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
8. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
9. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
10. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
11. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)